Keeping translational science on the fast track to curb COVID-19 pneumonia
No champion race car driver can win without a dedicated pit crew. The same is true in medical research. Thanks to their “pit crew” Mayo Clinic researchers were able to repurpose an experimental therapy, called lenzilumab, for patients with COVID-19 pneumonia, and from there into a phase three clinical trial — all in about one year.
"I think we’ve accomplished in this year what normally would take seven years," says Saad Kenderian, M.B., Ch.B., a Mayo Clinic cancer researcher.
Claudia Lucchinetti, M.D., director of Mayo Clinic’s Center for Clinical and Translational Science (CCaTS) says the way the science, people, and resources came together was extraordinary and that “it wouldn’t have happened just about anywhere else but at Mayo Clinic.”
Jenny Weis, research administrator for CCaTS, agrees. "We assembled the ‘A-Team. We took what we were already experts at and we held hands and we sprinted.”